Unicycive Therapeutics, Inc.
UNCY
$6.93
-$0.19-2.67%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -144.06% | 6.78% | -1,231.05% | 102.65% | -425.51% |
| Total Depreciation and Amortization | 2.03% | 7.25% | 2.22% | 0.75% | 8.94% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2,635.61% | -271.07% | 102.53% | -159.24% | 1,243.69% |
| Change in Net Operating Assets | -969.20% | 110.27% | -26.60% | -207.11% | 141.21% |
| Cash from Operations | -34.72% | 29.19% | 5.43% | -35.97% | 29.23% |
| Capital Expenditure | 100.00% | 66.67% | 62.50% | 27.27% | 8.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -603,450.00% | 66.67% | 62.50% | 27.27% | 8.33% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -74.91% | 139.60% | 306.09% | 308.49% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 74.85% | -135.55% | -41.80% | 23.27% | -102.55% |
| Cash from Financing | -74.91% | 139.73% | 331.42% | 597.53% | 332.48% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -166.27% | 696.25% | 140.14% | -2.71% | 34.22% |